









2. Editorial. Long COVID: let patients help define long-lasting COVID symptoms. *Nature* 2020;586:170.
3. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:993-8.
4. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. *JAMA* 2020;324:603.
5. Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *J Infect* 2020 [Epub ahead of print].
6. Sollini M, Ciccarelli M, Cecconi M, et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/CT study. *Eur J Nucl Med Mol Imaging* 2020 [Epub ahead of print].
7. Slart RHJA. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. *Eur J Nucl Med Mol Imaging* 2018;45:1250-69.
8. Manson JJ, Crooks C, Naja M, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. *Lancet Rheumatol* 2020 [Epub ahead of print].
9. Becker RC. COVID-19-associated vasculitis and vasculopathy. *J Thromb Thrombolysis* 2020;1-13.
10. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. *J Thromb Thrombolysis* 2020;50:54-67.
11. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. *Eur Heart J* 2020;41:3038-44.
12. Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. *Lancet Respir Med* 2020 [Epub ahead of print].
13. Kermani TA, Warrington KJ, Amin S. Malignancy risk in vasculitis. *Ther Adv Musculoskelet. Dis* 2011; 3:55-63.
14. Manger B, Schett G. Rheumatic paraneoplastic syndromes - A clinical link between malignancy and autoimmunity. *Clin Immunol* 2018;186:67-70.
15. Benharroch D, Osyntsov L. Infectious diseases are analogous with cancer. Hypothesis and implications. *J Cancer* 2012;3:117-21.
16. Bakouny Z, Hawley JE, Choueiri TK, et al. COVID-19 and cancer: current challenges and perspectives. *Cancer Cell* 2020;38:629-46.
17. Grifoni E, Valoriani A, Cei F, et al. Interleukin-6 as prognosticator in patients with COVID-19. *J Infect* 2020;81:452-82.
18. Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. *BMJ Evidence-Based Med* 2020;bmjebm-2020-111536.
19. Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. *Thromb Haemost* 2020;120:876-8.
20. Bianconi V, Violi F, Falorni F, et al. Is acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19? *Drugs* 2020;1-14.
21. Frohman EM, Villanarette-Pittman NR, Cruz RA, et al. Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack. *J Neurol Sci* 2020;415:116935.
22. Byrnie G, Dua A, Husainat N, et al. American College of Rheumatology (ACR) Vasculitis Guideline; Updated 2019. Available from: <https://www.rheumatology.org/Portals/0/Files/Vasculitis-Guideline-Project-Plan-Large-Medium-Vessel.pdf>
23. Raymond E, Thieblemont C, Alran S, Faivre S. Impact of the COVID-19 outbreak on the management of patients with cancer. *Target Oncol* 2020 [Epub ahead of print].

Non-commercial use only